Lifileucel plus pembrolizumab shows 62.5% response rate in frontline advanced melanoma with durable survival.

Iovance Biotherapeutics announced that their lifileucel TIL cell therapy combined with pembrolizumab achieved a 62.5% objective response rate and 29.2% complete response rate in a Phase 2 trial for frontline advanced melanoma. The median overall survival was not reached after more than four years of follow-up, indicating durable benefit. These results, presented at ESMO 2026, support ongoing Phase 3 trials aiming for approval of this combination as a frontline treatment. This therapy addresses a significant unmet need as many patients do not benefit long-term from current immunotherapies.

Iovance Biotherapeutics stock trades at USD 13.77 on Pluang as of Oct 23, 2026 21:32 WIB, down 2.65% in one day. The company holds a market cap of $6.41 billion with a trading volume of 10,765,088 shares. This price is near its 52-week high of $14.86, reflecting ongoing investor interest in its advanced melanoma therapy progress.